Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study

Clinical Chemistry

Volumn 42, Issue 4, 1996, Pages 507-514

  Contois, John H ^a,b,d   Mcnamara, Judith R ^a   Lammi Keefe, Carol J ^b   Wilson, Peter W F ^c   Massov, Tatyana ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

coronary heart disease; epidemiology; lipids; lipoproteins; standardization

Indexed keywords

APOLIPOPROTEIN A1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; STANDARD; TURBIDIMETRY;

EID: 0029947334     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.4.507     Document Type: Article

References (43)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977;62:707-14.
2. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis [Review]. Am Heart J 1987;113:589-97.
3. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO, for the MRFIT Research Group. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT Multiple Risk Factor Intervention Trial. Am Heart J 1986;112:825-36.
4. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA, for the LRC Program. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation 1986;74: 1217-25.
5. Manninen V, Elo O, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA 1988;260:641-51.
6. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: implications for treatment. Circulation 1992;85:37-45.
7. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
8. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
9. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma apolipoprotein A-I absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982;2:16-26.
10. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high density-lipoprotein. Biochemistry 1988;27:25-9.
11. Barbaras R, Puchois P, Fruchart J-C, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun 1987;142: 63-9.
12. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-7.
13. Avogaro P, Bittolo Bon G, Cazzolato G, Rorai E. Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis 1980; 37:69-76.
14. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983;309: 385-9.
15. Durrington PN, Hunt L, Ishola M, Kane J, Stephens WP. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J 1986;56: 206-12.
16. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I, B as predictors of angiographically defined coronary heart disease. Arch Intern Med 1990;150:1629-33.
17. Tasaki H, Nakashima Y, Nandate H, Yashiro A, Kawashima T, Kuroiwa A. Comparison of serum lipid values in variant angina pectoris and fixed coronary artery disease with normal subjects. Am J Cardiol 1989;63:1441-5.
18. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Henneckens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
19. Ishikawa T, Fidge N, Thelle DS, Førde OH, Miller NE. The Tromsø Heart Study: serum apolipoprotein AI concentration in relation to future coronary heart disease. Eur J Clin Invest 1978;8:179-82.
20. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992;69:1251-4.
21. Coleman MP, Key TJ, Wang DY, Hermon C, Fentiman IS, Allen DS, et al. A prospective study of obesity, lipids, apolipoproteins and ischemic heart disease in women. Atherosclerosis 1992;92:177-85.
22. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991;37: 1676-82.
23. Albers JJ, Marcovina SM, Kennedy H. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-62.
24. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81.
25. Wilson PWF, Christianson JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. JAMA 1989;262:41-4.
26. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
27. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83.
30. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res 1990;31:645-52.
31. DeLamatre J, Wolfbauer G, Phillips MC, Rothblat GH. Role of apolipoproteins in cellular cholesterol efflux. Biochim Biophys Acta 1986;875:419-28.
32. Oram JF. Effects of high density lipoprotein subfractions on cholesterol homeostasis in human fibroblasts and arterial smooth muscle cells. Arteriosclerosis 1983;3:420-32.
33. Kinlay S, Dobson AJ, Heller RF, Dickeson JE, Ryan S. Lipid and apolipoprotein levels in an Australian community. Med J Aust 1991;154:170-5.
34. Meilahn EN, Kuller LH, Stein EA, Caggiula AW, Matthews KA. Characteristics associated with apoprotein and lipoprotein lipid levels in middle-aged women. Arteriosclerosis 1988;8:515-20.
35. Zunic G, Jelic-Ivanovic Z, Spasic S, Stojiljkovic A, Majkic-Singh N. Reference values for apolipoproteins A-I and B in healthy subjects, by age. Clin Chem 1992;38:566-9.
36. Garrison RJ, Wilson PWF, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism 1980;29:1053-60.
37. Willett W, Hennekens CH, Castelli W, Rosner B, Evans D, Taylor J, Kass EH. Effects of cigarette smoking on fasting triglyceride, total cholesterol, and HDL-cholesterol in women. Am Heart J 1983; 105:417-21.
38. Garrison RJ, Kannel WB, Feinleib M, Castelli WP, McNamara PM, Padgett SJ. Cigarette smoking and HDL cholesterol: the Framingham Offspring Study. Atherosclerosis 1978;30:17-25.
39. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994;35:871-82.
40. Alvarez C, Orejas A, Gonzalez S, Diaz R, Colomo LF. Reference intervals for serum lipids, lipoproteins, and apolipoproteins in the elderly. Clin Chem 1984;30:404-6.
41. Spagnolo A, Menotti A, Giampaoli S, Morisi G, Buongiorno A, Urbinati GC, et al. High density lipoprotein cholesterol distribution and predictive power in some Italian population studies [Review]. Eur J Epidemiol 1989;5:328-35.
42. Waller KV, Ward KM, Rudmann SV. Serum lipids, lipoproteins, and apolipoproteins in the healthy elderly. Lab Med 1992;23:109-14.
43. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988;67:30-5.